Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rigshospitalet, Denmark
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre Oscar Lambret
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
University Hospital, Caen
National Cancer Institute (NCI)
Boehringer Ingelheim
Washington University School of Medicine
OHSU Knight Cancer Institute
University of Southern California
Seagen Inc.
Genmab
Allist Pharmaceuticals, Inc.
SONIRE Therapeutics Inc.
Servier
Fudan University
Karolinska Institutet
Eastern Cooperative Oncology Group
Seagen Inc.
Massachusetts General Hospital
Ono Pharmaceutical Co. Ltd
Eli Lilly and Company
Pfizer
H. Lee Moffitt Cancer Center and Research Institute